.png)
Life Science Innovation Network Japan (LINK-J) , BioLabs and Mitsui Fudosan Co., Ltd. announce that they have been selected for the Tokyo Metropolitan Government's "TIB CATAPULT (Cluster Creation Project to Challenge Global Innovation)" program and have launched the startup incubation cluster, "LINK-BioBAY TOKYO". This collaboration, with expertise in Japan and the US, will support the growth of Japanese life science startups globally.
As part of our supports, we will launch the Masterclass Program by BioLabs this summer.
Startups selected for it will receive the following support:
- Online webinars: 6 times
- Online mentorings: 8 times
- Online pitch coaching: 2 times
- On-site workshops
- An opportunity to present at a demo day attended by corporations and investors
We welcome applications from life sciences startups aiming for global growth!
Application Guidelines
Application Requirements
[Business Area]
Discovery-stage life science startups (Preferred human health technologies – therapeutics, devices, diagnostics)
[Business Stage]
- Established company with 1-10 employees, ready to learn how to scale to global stage
- Startup that has been established for less than 10 years since its founding
- Funding stage: Preferred Pre-seed, Seed, working to raise Series A VC funding
- Own their IP, or exclusive use license from university or other spinout entity
[Language]
Applicants must be able to communicate at a business level in English.
Note: All contents including document screening, pitch screening, lectures, mentoring, and demo day in this program will be conducted in English.
[Other Requirements]
Applicants must be
- able to disclose business details as non-confidential information.
- able to participate in all selection processes leading to the final selection.
- able to participate in all events and programs planned in this program.
- conducting business in Tokyo or have plans/intention to do so in the future.
Application Method and Screening Process
(1) Application Schedule
Document Submission Period | Until 5:00pm on July 9, 2025 |
Notification of Document Screening Results (*1) | Scheduled for July 15, 2025 Applicants who pass the document screening will proceed to the pitch screening. |
Pitch Screening (Online) (*2) | Scheduled for July 18, 2025, from 7:00 to 9:00AM (Japan time) Each company will have 8 minutes for the pitch and 5 minutes for Q&A. |
Final Screening Results Notification | Scheduled for July 23, 2025 |
(*1) The results of the document screening will be notified via email, regardless of the outcome.
(*2) The schedule for the pitch screening day will be separately notified to those who pass the document screening.
(2) Submission Documents
Please prepare and submit the following materials in English.
Overview | Company Overview and Business Overview (PDF format) |
Aspiration | Aspiration Sheet including the following information: - What you aim to achieve and expect from this program (PDF format) |
*Please limit the disclosure to non-confidential information. We cannot be held responsible for any confidential information disclosed.
(3) Document Submission Method
Please upload via the entry form.
Submit the documents with the file names "TIB_CompanyName_Overview" and "TIB_CompanyName_Aspiration".
(4) Screening Process
Document Screening -> Pitch Screening -> Selection of Companies
Approximately five companies will be selected.
Important Notes
- If your application includes confidential information or deviates from the application conditions, any resulting compensation, claims, or issues will be the sole responsibility of the applicant. The organizers, co-organizers, and sponsors will not be held responsible for any such matters.
- Applications with incomplete or false information will not be considered for screening.
- We cannot respond to inquiries regarding the screening content.
- The program content may change due to the organizer's circumstances. Please understand this in advance.
- Due to time differences, the program may be conducted outside of regular business hours.
Program Overview
Please refer to the schedule below for the overall program.
The planned dates are provisional and subject to change.
Virtual program
Agenda | Planned dates (Japan time) |
Kick-off | |
Program kick-off meeting | Aug 22 *Including the first webinar, it is scheduled to be held for approximately two hours starting at 7 am *To be held in a hybrid or an online format |
Needs assessment calls | |
Needs assessment calls | July 31 - Aug 12 |
Webinars | |
Webinar #1 - #6 | Aug 22 Sep 12 Oct 3 Nov 14 Dec 5 Jan 16 *Each webinar is scheduled from 7 am to 8 am |
Virtual Mentoring | |
Session #1 - #8 | Aug 27 - Dec 19 |
Pitch coaching sessions | |
Pitch coaching | Sep 15 - Oct 9 *Two 30-min sessions per startups |
Follow-up | |
Follow-up calls | Jan 21 - Jan 26, 2026 |
Tokyo Biotech day (In-person program)
Agenda | Planned dates (Japan time) |
2 workshops / Pitch / Networking event | Oct 16 |
Judges & Mentors
Pitch Screening Judges

Masahiro Takeuchi, Ph.D.
Special Advisor, LINK-J
Special Advisor, Life Science Innovation Department, Innovation Promoting Division, Mitsui Fudosan Co., Ltd
After earning a Ph.D. in Science from Kyoto University Graduate School in 1993, joined Astellas Pharma (formerly Yamanouchi Pharmaceutical). Gained experience in research operations in both the U.S. and Japan, managed partnerships with domestic and international academia and venture companies, led post-merger integration (PMI) of overseas companies, and served as Head of the Oncology Unit. After working as a science advisor for a venture company, joined Mitsui Fudosan in 2021.

Ikuo Hayashi, Ph.D.
General Manager, LINK-J
Special Advisor, Life Science Innovation Department, Innovation Promoting Division, Mitsui Fudosan Co., Ltd
After working as a postdoctoral researcher at the University of Tokyo, he worked as a researcher at pharmaceutical companies both domestically and internationally. In May 2020, he joined the Bayer's Open Innovation Center Japan, where he was involved in managing startup support programs and shared labs. Since May 2023, he has been in his current position, contributing to the cultivation of the life sciences innovation ecosystem. He is a licensed pharmacist and holds an MBA from the University of California, San Diego.

Hiroko Yasuga, Ph.D.
Producer, LINK-J
Worked as a research assistant in a pharmaceutical company before going to the UK, where studied immunology at Imperial College London (ICL). After studying at ICL, undertook doctoral research on autoimmune diseases at Nanyang Technological University/Agency for Science, Technology and Research (A*STAR) in Singapore. Later, returned to Japan and worked in medical affairs for major pharmaceutical companies, where involved in pre-launch activities for new drugs in the immunology field and post-launch activities for drugs in the neurological disease field.
Since July 2024, started the current position and contributing in fostering the life science innovation ecosystem, promoting overseas collaboration and the accelerator programme UNIKORN at the Life Science Innovation Network Japan (LINK-J). Doctor of Science.

Laura Stevens, Ph.D.
Sr. Project Manager Business Development, BioLabs
Laura Stevens, PhD, is a Senior Project Manager in the Business Development group at BioLabs. Biolabs is a global operator of laboratory co-working facilities for life science start-ups. Dr. Stevens manages BioLabs’ portfolio of business expansion projects, with a focus on new markets in North America and Asia. Dr. Stevens is also responsible for the development and deployment of enterprise-level company management processes to enable strategic growth, business case evaluation and feasibility, and efficient project execution.
A scientist by training, Dr. Stevens has a PhD in Cell and Developmental Biology from Vanderbilt University School of Medicine, where her work focused on tissue regeneration and wound healing. Following graduate school, Dr. Stevens moved to Boston, MA, where she worked as a senior research scientist at multiple start-up pharmaceutical companies, developing small molecules targeting autoimmunity and inflammation indications. Transitioning to the business side of biotech, Dr. Stevens managed multi-national, high-throughput screening projects, as well as daily lab and business operations, for a an early-stage startup company developing inflammatory cell death therapeutics. As a former resident of BioLabs’ sister company, LabCentral, Dr. Stevens has first-hand experience as a user working within the BioLabs/LabCentral business model.
Dr. Stevens is based at BioLabs’ headquarters office in Cambridge, MA.
...and more from BioLabs team
Application Consultation Meeting
Online information sessions will be held for companies considering applying to this program.
*The content of the first and second sessions will be the same.
#1
Date and Time: Thursday, June 26, from 10:00 to 11:00 AM
Location: Zoom Webinar
Registration: https://evententry.link-j.org/public/seminar/view/11518
#2
Date and Time: Wednesday, July 2, from 14:30 to 15:30
Location: Zoom Webinar
Registration: https://evententry.link-j.org/public/seminar/view/11519
Organizers
Life Science Innovation Network Japan (LINK-J)
BioLabs Global, Inc.
Contact
LINK-J secretariat
Contact Persons: Yasuga, Imoto, Katayama
E-mail: contact@link-j.org